Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AHOD0831||COG||A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|10015||ETCTN||A Non-Randomized; Open-Label; Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma||Adult CIRB - Early Phase Emphasis||Available to Open|
|PBTC-049||PBTC||A Pediatric Brain Tumor Consortium Phase I/II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma||Pediatric CIRB||Available to Open|
|PBTC-053||PBTC||A Pediatric Brain Tumor Consortium Phase I/II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma||Pediatric CIRB||Available to Open|
|ADVL06B1||COG||A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer: A Group-Wide Non-Therapeutic Study||Pediatric CIRB||Completed|
|10066||ETCTN||A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|10076||ETCTN||A Phase 1 Dose-Escalation And Exploratory Dose Expansion Study Of AMG 232 In Combination With Carfilzomib, Lenalidomide, And Dexmethasone In Relapsed And/Or Refractory Myeloma||Adult CIRB - Early Phase Emphasis||Available to Open|
|9844||ETCTN||A Phase 1 Study Evaluating Safety; Tolerability; and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|ADVL1514||COG||A Phase 1 Study of ABI-009 (nab-Rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors; Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan||Pediatric CIRB||Available to Open|
|9824||ETCTN||A Phase 1 Study of alisertib (MLN8237) in combination with mFOLFOX in gastrointestinal tumors||Adult CIRB - Early Phase Emphasis||Available to Open|